Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Oktober 2020

Planlagt Fastgjort Låst Flyttet Genmab
767 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #635

    good morning 😉

    1 Reply Last reply
    0
    • K Offline
      K Offline
      kkjoel
      wrote on sidst redigeret af
      #636

      And good mornings to The ELectrician 😉 I didn't have a target from GS, so it must be quite an old (and ridiculously low) one, 1,112?! But classically executed, none the less: buy, buy, buy yourself (having a target of 1,112 and a price of 2,200.. so that makes a lot of sense) - THEN recommend buy to all others.

      1 Reply Last reply
      0
      • K Offline
        K Offline
        kkjoel
        wrote on sidst redigeret af
        #637

        Must be extremely positive for GEN 2day w GS recommendation. AND NBI up 0,5% yday. Let'
        s see...

        1 Reply Last reply
        0
        • K Offline
          K Offline
          kkjoel
          wrote on sidst redigeret af
          #638

          All right, they didn't recommend buy, but they more than doubled the TP. Same, same....

          1 Reply Last reply
          0
          • SolsenS Offline
            SolsenS Offline
            Solsen
            wrote on sidst redigeret af
            #639

            Har valgt at reducere lidt på GS analysen, der har holdt hånden under Genmab. Det ligner en blodig dag med lockdowns trusler og smittetal der skræmmer.

            1 Reply Last reply
            0
            • SolsenS Offline
              SolsenS Offline
              Solsen
              wrote on sidst redigeret af
              #640

              Men håber at Genmab stiger 🙂

              1 Reply Last reply
              0
              • SEACOPS Offline
                SEACOPS Offline
                SEACOP
                wrote on sidst redigeret af
                #641

                Peak March 2021. 🙂 https://financhill.com/stock-forecast/GMAB-stock-prediction

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #642

                  Novartis (NVS) CEO, Vas Narasimham on Q3 2020 Results - Earnings Call Transcript https://seekingalpha.com/article/4381882-novartis-nvs-ceo-vas-narasimham-on-q3-2020-results-earnings-call-transcript?part=single

                  1 Reply Last reply
                  0
                  • BulderB Offline
                    BulderB Offline
                    Bulder
                    wrote on sidst redigeret af
                    #643

                    Nice: "If you look at some of the estimates on what the B-cell market could look like over the next 10 years, there are some estimates that point us to 35% to 40% of the market."

                    1 Reply Last reply
                    0
                    • SolsenS Offline
                      SolsenS Offline
                      Solsen
                      wrote on sidst redigeret af
                      #644

                      Thats a lot 🙂

                      1 Reply Last reply
                      0
                      • BulderB Offline
                        BulderB Offline
                        Bulder
                        wrote on sidst redigeret af
                        #645

                        Lad os antage at det svarer til 4 mia $. 10% heraf er 400 mio $.

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #646

                          PRAC agenda: 5.3.4. Carfilzomib - KYPROLIS (CAP) - EMEA/H/C/003790/II/0045, Orphan
                          Applicant: Amgen Europe B.V.

                          Scope: Extension of existing indication to include combination of Kyprolis (carfilzomib) with
                          daratumumab and dexamethasone. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the
                          SmPC are updated. The package leaflet is updated in accordance
                          Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

                          1 Reply Last reply
                          0
                          • BulderB Offline
                            BulderB Offline
                            Bulder
                            wrote on sidst redigeret af
                            #647

                            Professor ærgrer sig over Medicinrådets afvisning af Dar MPV https://haematologisktidsskrift.dk/2-uncategorised/768-professor-aergrer-sig-over-medicinradets-afvisning-af-dar-mpv.html

                            1 Reply Last reply
                            0
                            • Helge_LarsenPI-redaktørH Offline
                              Helge_LarsenPI-redaktørH Offline
                              Helge_LarsenPI-redaktør
                              wrote on sidst redigeret af
                              #648

                              Ses vi kl. 17? https://event.webinarjam.com/register/8/rp8nvfw

                              1 Reply Last reply
                              0
                              • BulderB Offline
                                BulderB Offline
                                Bulder
                                wrote on sidst redigeret af
                                #649

                                Belamaf på dansk https://haematologisktidsskrift.dk/sygdomme/myeloma/761-fda-haster-myelomatose-middel-ud-pa-markedet.html

                                1 Reply Last reply
                                0
                                • K Offline
                                  K Offline
                                  Klarussen
                                  wrote on sidst redigeret af
                                  #650

                                  Køber i 2050,- vi er der snart 😉

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #651

                                    New trial - A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies https://www.clinicaltrials.gov/ct2/show/NCT04606381?term=rHuPH20&lupd_s=10%2F27%2F2020&draw=2&rank=1

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #652

                                      exactly 100 dkk high -> low . #UselessFacts

                                      1 Reply Last reply
                                      0
                                      • G Offline
                                        G Offline
                                        GeorgeBest
                                        wrote on sidst redigeret af
                                        #653

                                        https://twitter.com/wattwurm73/status/1321464818776375296?s=21 HALOs teknologi anvendes også til Amivantamab sc!

                                        1 Reply Last reply
                                        0
                                        • G Offline
                                          G Offline
                                          gentogen
                                          wrote on sidst redigeret af
                                          #654

                                          Regarding the new Amivantamab: Eligible tumor types include non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), hepatocellular cancer (HCC), colorectal cancer (CRC), renal cell cancer (RCC), medullary thyroid cancer (MTC), gastroesophageal cancer (GEC), mesothelioma, breast cancer (BC) and ovarian cancer (OC).

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger